A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
Tianjin Cancer Hospital (Tianjin Medical University Cancer Hospital) is the birthplace of oncology in China. It is a large tertiary first-class oncology hospital integrating medicine, teaching, research, and prevention.
Tianjin, China Clinical Trial Location
Tianjin Medical University Cancer Institute and Hospital
Binshui Rd, Hexi District,
Tianjin, Tianjin, China